New drug combo tested to shrink lung tumors before surgery

This study is testing whether adding an investigational drug called SYS6010 to the standard drug osimertinib is more effective at shrinking tumors before surgery for patients with a specific type of lung cancer (EGFR-positive, non-squamous NSCLC). It will enroll 120 adults with stage II-IIIB cancer who have not had prior treatment. The main goal is to see if the combination leads to more patients having very little or no cancer left in the tumor removed during surgery.